1 / 6

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter,

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial. Authors: Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group Reviewer: Dr. Chris Booth Date posted: December 12 2007.

zalika
Télécharger la présentation

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial Authors: Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupReviewer: Dr. Chris Booth Date posted: December 12 2007

  2. Treatment A: • 21 day cycles • Gem 1000mg/m2 D1 and 8 • Cape 650 mg/m2 for 14 days R • Treatment B: • Burris regimen • 1000 mg/m2 7/8 weeks, then ¾ weeks Locally advanced/ Metastatic Pancreas cancer Primary endpoint: overall survival Secondary endpoints: PFS, ORR, safety, QOL

  3. RESULTS

  4. STUDY COMMENTARY •  Single agent Gem is current standard for advanced/locally advanced PC •  Clinical benefit and small OS benefit over 5-FU •  Multiple trials have added “something” to Gem with no (or little) success - For a comprehensive review please see Van Cutsem et al. JCO 2007. (reference) - NCIC CTG PA.3 trial was the first study to show a survival benefit (albeit a modest one) with the addition of erlotinib to gemcitabine (reference)

  5. STUDY COMMENTARY CONTINUED ESMO 2005 - Interim data presented for RCT in UK of Gem-Cap vs Gem - Median survival 7.4 vs 6 months (p=0.014) - ORR 14 vs 7% (p=0.0001) - OS at 1 year 26 vs 19% - This has led to some change in practice in Canada and US despite the fact that 2 years later ths data have not yet been published in full The current well designed study failed to detect any improvement in outcome with the addition of Capecitabine to Gemcitabine - Post-hoc sub-group analysis suggests benefit to Cape-Gem among patients with good performance status (OS 10.1 vs 7.4 mos, p=0.014)  No QOL data presented in the current article

  6. BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS • This study does not support the use of Gem-Cape over Gem along in patients with advanced pancreas cancer • Results are discordant with the UK study presented at ESMO 2005 • - Doses of Gem and Cape were higher in the UK study • Until the UK study is published in full, the standard of care for advanced pancreas cancer remains single agent Gemcitabine

More Related